Fresenius Kabi Oncology Ltd Financial Ratios
FKONCO · Healthcare · Current price
P/E ratio
—
P/B ratio
—
ROE
11.2%
ROCE
9.0%
Debt / Equity
—
Dividend yield
—
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | — | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | — | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 11.2% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 9.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | — | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Fresenius Kabi Oncology Ltd's latest numbers.
Fresenius Kabi Oncology Ltd profitability
Fresenius Kabi Oncology Ltd generates a return on equity of 11.2% and a return on capital employed of 9.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of n/a and a P/E of —, Fresenius Kabi Oncology Ltd is conservatively financed. Our overall business-quality score for the company is 3.4 / 10.
Understand the ratios
More on Fresenius Kabi Oncology Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.